Signal transducer and activator of transcription-3(STAT3) activation is key for ischemic postconditioning(IPo) to attenuate myocardial ischemia-reperfusion injury(MIRI), but IPo loses cardioprotection in diabetes whose cardiac STAT3 activation is impaired and adiponectin reduced. We found that IPo increased post-ischemic cardiomyocyte-derived adiponectin, activated mitochondrial STAT3(mitoSTAT3), improved mitochondrial function and attenuated MIRI, in wild-type but not in adiponectin knockout(Adipo 
Introduction
Myocardial infarction is a major perioperative complication in patient with diabetes(1).
Reperfusion therapies restore coronary flow, but itself may cause lethal tissue injury called "reperfusion injury". Ischemic postconditioning(IPo), the phenomenon that brief repetitive episodes of ischemia reperfusion(IR) at the immediate onset of reperfusion, can protect the hearts against myocardial IR injury(2), which needs to activate signal transducer and activator of transcription 3(STAT3) (3) . However, how IPo activates STAT3 remains unclear.
In addition, hearts from diabetic subjects are less or not sensitive to IPo and the mechanism is unknown (4) . The reduction of myocardial STAT3 activation in diabetes and the subsequent reduction of myocardial nitric oxide(NO) bioavailability(5) may be primarily responsible for and the left anterior descending coronary artery was occluded for 30 minutes and followed by reperfusion for 2 hours(to assess post-ischemic mRNA and protein expressions of cardiac APN and other signaling molecules) or 24 hours(to assess post-ischemic cardiac function, myocardial injury and infarct size) (6) . IPo was produced by 3 cycles of 10s of re-occlusion and 10s of reperfusion immediately after ischemia(18). All assays were performed using tissue from ischemic/reperfused area or area-at-risk identified with Evens blue negative staining. Myocardial infarct size was determined by the Evans blue/TTC staining as described (9) , and the operators were blinded to the information of study design and intervention. The global cardiac functions were monitored by using a pressure-volume conductance catheter and analyzed using Labchart 8 software(AD Instruments, Colorado Springs, CO, USA) as we described(19).
Detection of myocardial apoptosis
Myocardial apoptosis was determined by TUNEL staining using an in situ cell death detection kit(Roche Diagnostics GmbH, Mannheim, Germany) as described (20) . The sections were observed in the light microscope by an investigator who was initially blinded to treatment groups, and five randomly selected fields of each slide were analyzed, and the apoptotic index was calculated as a percentage of apoptotic nuclei to total nuclei.
Electron microscopic analysis
Heart tissues were fixed with 2.5% glutaraldehyde in 0.1 mol/L phosphate buffer(pH 7.4), followed by 1% OsO4. After dehyderation, thin sections were stained with uranyl acetate and lead citrate for observation under a JEM 1011CX electron microscope. Images were acquired digitally.
Induction of diabetes and adiponectin adenovirus infection
Type 1 diabetes was induced via signal tail vein injection of STZ injection(65 mg/kg, Sigma-Aldrich, St. Louis, MO) as described(21). One week after STZ injection, rats exhibiting hyperglycemia(blood glucose 16.7 mmol/L or above) were considered diabetic and subjected to outlined experiments. Recombinant adiponectin adenovirus(1*10 9 pfu) was used to overexpress adiponectin in vivo and luciferase used as control, which were tail-vein-injected into rats 1 week prior to inducing IR as described(19).
Measurement of mitochondrial respiratory chain complex activities
At the end of experiments, heart tissues were immediately collected for cardiac mitochondria isolation according to the manufacturer's protocol per the mitochondria Extraction Kit(Thermo, Chicago, IL). The resulting mitochondrial pellets were resuspended in tris-droxymethylaminomethane solution(pH 8.0) and kept at -80°C for subsequent measurements of mitochondrial respiratory chain complex activities(Complex I-V) as described(22).
Determination of 15-F 2t -isoprostane, NO, nitrotyrosine, ATP content, and reactive oxygen species(ROS)
Cardiac tissue(area-at-risk) was rinsed and homogenized. Plasma and heart tissue free determined by the Griess reaction as described (13) . Myocardial nitrotyrosine levels were determined using the Nitrotyrosine Assay kit per the manufacturer's protocol(Millipore).
6 DNA(nDNA) contamination nDNA forward: ATGGAAAGCCTGCCATCATG, reverse:
TCCTTGTTGTTCAGCATCAC; mtDNA forward: CCTATCACCCTTGCCATCAT, reverse:
GAGGCTGTTGCTTGTGTGAC. The PCR reactions were performed using an Applied Biosystems Prism 7000 sequence detection system. Relative quantification of the copy number of mtDNA was analyzed using nDNA as the standard. Total RNA was extracted using Trizol(Invitrogen Life Technologies, Carlsbad, CA), and quantitative real-time PCR was performed with a SYBR green PCT master mix(Takara Shuzou, Japan) on a Applied
Biosystems Prism 7000 sequence detection system. Gene-specific primers were as follows: 
Adult mouse and rat cardiomyocytes isolation and hypoxia/reoxygenation(HR)
Calcium-tolerant cardiomyocytes were prepared from rat/mouse ventricles via a modified method as described (13) . Mice cardiomyocytes were treated with stattic(a specific STAT3
inhibitor, 100 µmol/L, 1 hour before HR), or methyl-β-cyclodextrin(CD, a disrupter of cholesterol-rich caveolae, 10 mmol/L, 30 minutes before HR), or recombinant globular adiponectin(gAd, 2 µg/mL, for 24 hours), before being subjected to HR and hypoxic postconditioning(HPo). Rat cardiomyocytes were incubated in normal glucose(NG, 5.5 mM)
or high glucose(HG, 25 mM) for 18 hours or 38 hours. Some of the subgroups were subjected to HR and HPo. HR was achieved by hypoxia for 45 minutes followed by 2 hours of reoxygenation(25 
Immunoprecipitation
Isolated cardiomyocytes or heart tissue were homogenized in lysis buffer. A total of 500 mg extracts were subjected to immunoprecipitation with 2 mg Cav3 primary antibody in the presence of 20 mL protein A/G PLUS-Agarose. After extensive PBS washes, the immunoprecipitates were denatured with SDS loading buffer and subjected to analysis for AdipoR1 or AdipoR2 expression by Western blot as described below.
GraphPad Prism(GraphPad Software, San Diego, CA). P values< 0.05 were considered statistically significant. 1A ) and increased cardiac mitoSTAT3 phosphorylation at site Ser727 in WT but not in Adipo -/-mice( Fig.2A-C 2D ) and reduced cardiac ATP production( Fig.2E ) and more severe mitochondrial damage manifested as significant morphological defects (mitochondrial swelling and dissolving) and a reduction of mtDNA to nDNA ratio( Fig.2F and G) concomitant with decreases of mRNA expression of Tfam, Nrf1, and Ppargc1a(Supplemental Fig.1B-D) . IPo significantly increased mitochondrial complex I/IV/V(but not complex II and III) activities, increased myocardial ATP production, attenuated mitochondrial morphologic changes, increased mtDNA/nDNA, and upregulated mRNA expression of Tfam, Nrf1, and Ppargc1a in WT but not in Adipo -/-mice( Fig.2D-G) .
Results

Myocardial
Lack of APN Compromised IPo Induced Increases in Nitric Oxide Production and eNOS
Expression and Reduction in Myocardial Oxidative Stress
Post-ischemic cardiac NO was significantly reduced that was associated with decreased eNOS phosphorylation at site Ser1177 and increased nitrotyrosine formation in both WT and Adipo -/-mice, and IPo attenuated all these changes in WT but not in Adipo -/-mice(Supplemental Fig.2A-C) . Similarly, IR-induced myocardial oxidative stress was more pronounced in Adipo -/-mice, evidenced as elevated cardiac and plasma levels of 
Adiponectin Restored Heart Sensitivity to IPo Cardioprotection by Activating MitoSTAT3 in 4-week But Not in 8-week Diabetic Rats
Post-ischemic myocardial injury was significantly increased evidenced as increased infarct size and plasma CK-MB release in both 4-week and 8-week diabetic rats(Supplemental Table.2 and Table. 3). Plasma APN was significantly elevated after APN injection but no significant change of cardiac APN protein expression were observed in both 4-week and 8-week diabetic rats before or after IR and IPo(Supplemental Fig.6C-D) . IPo had no significant impact on post-ischemic cardiac APN protein expression in diabetic rats irrespective of APN supplementation (Supplemental (Fig.6E) . Also, mitochondrial complex I/II+III/IV/V activities were significantly increased after APN supplementation and were further enhanced by IPo, but these beneficial effects of IPo were abolished by AG490 (Fig.6F ). APN supplementation alone or in combination with IPo significantly attenuated post-ischemic mitochondrial damage(reduction of cytochrome C release) and reduced cardiac free 15-F 2t -isoprostance formation, while these beneficial effects of APN were abolished by AG490( Fig.6G-H ).
IPo Lost Cardioprotection in Diabetic Rats Due to the Inability to Activate MitoSTAT3
Subsequent to the Impairment of AdipoR1/Cav3
As shown in Fig. 7A -B, AdipoR1 but not AdipoR2 protein was progressively reduced from 1-week to 8-week of diabetic induction( Fig.7A-B) . The colocalization of AdipoR1 and Cav3 was significantly and progressively reduced after diabetic induction (Fig.7C) . In cardiomyocytes isolated from non-diabetic rats exposed to normal or high glucose for different durations, the colocalization of AdipoR1 and Cav3 was increased after 18 hours hours high glucose treatment (Fig.7E-F) . Similarly, in diabetic rats, AdipoR1 and Cav3 colocalization was significantly reduced in both 4-week and 8-week diabetic rats but was reversed by IPo in 4-week but not in 8-week diabetic rats (Fig.7G) .
Discussion
In information that there is a delay for APN to be shuttled from other compartments to the injured heart and that cardioprotection of IPo seen in our present study may be mainly through acutely/rapidly upregulating cardiomyocytes driven APN as confirmed in in vitro study in isolated cardiomyocytes (Fig.3) reversed the activities of mitochondrial complex I/IV/V, leading to increased ATP content and increased mtDNA to nDNA ratio (Fig.2) , and reduced myocardial oxidative stress and attenuated post-ischemic myocardial injury. We previously showed that APN attenuated post-ischemic myocardial dysfunction and apoptosis by decreasing NADPH oxidase expression and blocking peroxynitrite formation (6; 35) . In addition, we recently showed that administration of APN increased heme oxygenase-1 induction by concomitantly increasing Brg1 and Nrf2, which reduced myocardial oxidative stress and cardiac dysfunction in (36) . Similarly, in the current study, we found that IPo attenuated post-ischemic myocardial oxidative stress in WT but not in Adipo -/-mice(Supplemental Fig.2 ), suggesting that APN is required for IPo to confer cardioprotection through decreasing myocardial oxidative stress. NO represents one of the most important defense mechanisms against MIRI and is also one of the major mediators of IPo cardioprotection (37) . In the current study, IPo conferred cardioprotective effects through APN that was associated with reduced post-ischemic nitrotyrosine formation and increased cardiac NO production in WT but not in Adipo -/-mice. All these suggest that, IPo confers cardioprotection by reducing myocardial oxidative stress and increasing NO bioavailability through APN(Supplemental Fig.2A-B) . Thus, it is reasonable to postulate that inhibition of NO may abrogate APN-mediated IPo cardioprotection. This hypothesis deserves to be further investigated.
Further, in the present study, we found that the above-mentioned APN-mediated cardioprotective effects in IPo were abolished by STAT3 inhibition which was associated with increased ROS formation (Fig.3) , this indicates that APN-mediated mitoSTAT3 activation plays essential roles in IPo cardioprotection, especially in IPo-induced reduction of post-ischemic myocardial oxidative stress.
We previously showed that APN-mediated protection against MIRI is dependent on the activation of AdipoR1, the predominate form of AdipoRs in the heart (38) . Similarly, in the Increased oxidative stress in the heart of diabetic animals has been shown to be a major mechanism that renders the diabetic hearts less or not responsive to cardioprotective interventions that are otherwise effective in non-diabetes(4; 40), but the underlying mechanism is unclear. Plasma and cardiac APN levels are reduced in diabetic patients (41) and in STZ-induced diabetic rats(9; 42). Moreover, oxidative stress can down-regulate APN level(9; 43). Thus, reduced APN, in part as a consequence of increased oxidative stress in diabetes, should be responsible for the loss of IPo cardioprotection in diabetes. To this end, we used adenovirus to overexpress APN in diabetic rats and subjected them to IR and IPo.
Interestingly, supplementation of APN restored IPo cardioprotection by improving mitochondrial function and ameliorating oxidative stress subsequent to mitoSTAT3 activation( Fig.8 ), but these effects of APN were only seen in 4-week but not in 8-week diabetes. This promoted us postulate that the different responses to APN at 4-week and 8-week diabetes may be due to the impaired APN signaling in diabetes. After diabetes induction, AdipoR1 expression decreased progressively with the significant reduction at 4-week and 8-week, while AdipoR2 expression did not change. More importantly, the Of note, previously studies showed that APN exerts its metabolic regulative effects largely through the AMP-activated protein kinase(AMPK)-dependent pathway. However, our recent study (6) shows that, APN reduced post-ischemic myocardial injury via its antioxidative effects rather than through metabolic regulation. In addition, exogenous APN supplementation could attenuate myocardial apoptosis in cardiomyocytes subjected to HR by decreasing NADPH oxidase expression and blocking peroxynitrite formation in an AMPK-independent fashion (35) . These results strongly suggest that the degree of AMPK involvement in APN's biological functions is determined by the intracellular environment, particularly AMP concentration. Under pathological conditions(such as myocardial IR) in which intracellular AMP concentrations are elevated(47; 48), and AMPK has already been significantly activated, APN may exert its biological actions largely through signaling molecules other than AMPK. In the current study, we found that during IPo, APN activates STAT3 and subsequently reduces myocardial oxidative stress mainly through AdipoR1/Cav3.
Since we did not determine the change of AMPK in this process, we cannot exclude the possibility that AMPK may also play a role in this APN-induced STAT3 activation in IPo, and thus, further study regarding the role of AMPK in APN-mediated STAT3 activation in IPo is needed and its resolution will advance the understanding of IPo cardioprotection.
Conclusion
To our knowledge, our study firstly demonstrated that, IPo, by activating APN, activates STAT3 and leads to its mitochondrial shuttling, consequently improves post-ischemic cardiac mitochondrial function and attenuates myocardial injury, and that an intact AdipoR1/Cav3 signaling is critical for IPo to activate STAT3 through APN. Diabetes, by reducing APN and (Fig.8) .
Clinical perspectives
Despite 
